Quantcast
Last updated on April 24, 2014 at 13:30 EDT

Latest Actavis Stories

2013-08-16 08:23:49

PARSIPPANY, N.J., Aug. 16, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that James D'Arecca has joined the Company as Chief Accounting Officer, reporting to R. Todd Joyce, Chief Financial Officer - Global. Mr. D'Arecca joins Actavis from Bausch & Lomb, where he served in a similar role to his new Actavis position. Prior to Bausch & Lomb, he worked for Merck & Co, where he served as Executive Director & Business Development Controller. In this...

2013-08-15 12:29:28

DUBLIN, August 15, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fcrtlb/generic_growth) has announced the addition of the "Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs" [http://www.researchandmarkets.com/research/fcrtlb/generic_growth ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2013-08-09 08:25:04

PARSIPPANY, N.J. and DUBLIN, Aug. 9, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced that they have received approval from the French Competition Authority for Actavis' pending acquisition of Warner Chilcott. The companies previously received approval from the German Federal Cartel Office and have now received all ex-U.S. antitrust clearances required to complete the transaction. About ActavisActavis, Inc. (NYSE: ACT) is a...

2013-08-08 08:30:39

NEW YORK, August 8, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Zoetis Inc. (NYSE: ZTS), GlaxoSmithKline plc (ADR) (NYSE: GSK), Actavis Inc. (NYSE: ACT), Kindred Healthcare, Inc. (NYSE: KND), and TESARO Inc. (NASDAQ: TSRO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst...

2013-08-06 08:35:51

PARSIPPANY, N.J. and BARCELONA, SPAIN, Aug. 6, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Palau Pharma, S.A. today announced that Actavis Specialty Brands has acquired worldwide rights to Palau Pharma's Albaconazole development product, an oral antifungal agent for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications. Albaconazole is a new oral triazole discovered at Palau Pharma, with a potent broad-spectrum antifungal activity, and...

2013-08-02 16:23:30

PARSIPPANY, N.J., Aug. 2, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), today announced that Actavis Limited, Bank of America, N.A., as Administrative Agent and a syndicate of banks participating as lenders have entered into a new senior unsecured term loan credit and guaranty agreement, pursuant to which the lenders party to the agreement will provide loans, on the closing date of Actavis' proposed acquisition of Warner Chilcott plc (the "Closing Date"), to certain entities of...

2013-07-31 16:28:38

-- Companies Schedule Shareholder Meetings for September 10, 2013 -- PARSIPPANY, N.J. and DUBLIN, July 31, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Warner Chilcott plc (NASDAQ: WCRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC") by Actavis Limited ("New Actavis") on June 18, 2013 and amended on July 31, 2013 (the "Form S-4"), which includes a joint proxy statement of Actavis and Warner Chilcott,...

2013-07-30 08:33:59

NEW YORK, July 30, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Actavis Inc. (NYSE: ACT), Edwards Lifesciences Corp. (NYSE: EW), and Health Net, Inc. (NYSE: HNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-07-29 08:25:57

PARSIPPANY, N.J., July 29, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Tapentadol Extended-release Tablets 50 mg, 100 mg, 150 mg and 200 mg. Actavis' ANDA product is a generic version of Janssen Pharmaceuticals, Inc.'s Nucynta(® )ER, which is approved for the management of moderate to severe chronic pain in adults when a...

2013-07-16 08:26:26

NEW YORK, July 16, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Mylan Inc. (NASDAQ: MYL), Actavis, Inc. (NYSE: ACT), Warner Chilcott Plc (NASDAQ: WCRX), Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Today's readers may access these reports free of charge - including full price targets, industry...